Back to Search
Start Over
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease:Results of a post hoc analysis from a phase 3 trial
- Source :
- Leebeek , F W G , Peyvandi , F , Tiede , A , Castaman , G , Escobar , M , Wang , M , Zülfikar , B , Susen , S , Miesbach , W , Wang , S , Wang , Y , Zhang , J & Özen , G 2023 , ' Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease : Results of a post hoc analysis from a phase 3 trial ' , European Journal of Haematology , vol. 111 , no. 1 , pp. 29-40 .
- Publication Year :
- 2023
-
Abstract
- Objectives: To describe efficacy/safety of recombinant von Willebrand factor (rVWF) prophylaxis in patients with type 3 von Willebrand disease (VWD). Methods: This post hoc analysis of a phase 3 open-label trial provides a more detailed analysis of adults with type 3 VWD, categorized based on prior treatment at screening: “Prior On-Demand (OD)” (OD VWF; ≥3 documented spontaneous bleeding events [BEs] requiring VWF in previous 12 months) or “Switch” (plasma-derived [pd] VWF prophylaxis for ≥12 months). Annualized bleeding rates (ABRs) were evaluated during 12 months of rVWF prophylaxis versus historical data from medical records. Results: In the Prior OD group (n = 10), mean spontaneous ABR (sABR) for treated BEs was reduced by 91.6% (ratio, 0.08; 95% CI, 0.02–0.45) versus mean historical sABR. In the Switch group (n = 8), mean sABR for treated BEs was reduced by 47% (ratio, 0.53; 95% CI, 0.08–3.62). One non-serious adverse event (AE) was considered possibly related to rVWF. No treatment-related, fatal, or life-threatening serious AEs were reported, and no patient developed VWF inhibitors. Conclusions: rVWF prophylaxis reduced sABR in type 3 VWD patients previously treated with OD VWF therapy, and maintained a similar level of hemostatic control in those switching from pdVWF prophylaxis to rVWF prophylaxis.
Details
- Database :
- OAIster
- Journal :
- Leebeek , F W G , Peyvandi , F , Tiede , A , Castaman , G , Escobar , M , Wang , M , Zülfikar , B , Susen , S , Miesbach , W , Wang , S , Wang , Y , Zhang , J & Özen , G 2023 , ' Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease : Results of a post hoc analysis from a phase 3 trial ' , European Journal of Haematology , vol. 111 , no. 1 , pp. 29-40 .
- Notes :
- application/pdf, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1390850053
- Document Type :
- Electronic Resource